Generate:Biomedicines to Present Phase 1 Results for AI-Engineered Asthma Treatment

Sep 26, 2025
Generate:Biomedicines will present Phase 1 results for its AI-engineered asthma treatment, GB-0895, at the European Respiratory Society International Congress.

Generate:Biomedicines announced in a press release that it will present the Phase 1 results of its AI-engineered asthma treatment, GB-0895, at the European Respiratory Society International Congress in Amsterdam on September 28, 2025. GB-0895 is a next-generation, ultra-high affinity anti-TSLP monoclonal antibody designed for subcutaneous administration every six months.

The Phase 1 study involved 96 patients with mild to moderate asthma, demonstrating that GB-0895 was well tolerated across a wide dose range and showed dose-proportional pharmacokinetics with a prolonged half-life of approximately 89 days. The treatment also resulted in sustained reductions in eosinophils, FeNO, IL-5, and IL-13, supporting its potential for a biannual dosing regimen.

GB-0895 was developed using Generate:Biomedicines' generative biology platform, which integrates machine learning with high-throughput experimentation to optimize drug design. The platform aims to improve potency and half-life while maintaining specificity, offering a promising alternative for patients with respiratory diseases, including severe asthma.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.